|Drug Name||GPCR-targeted Project 017|
Frizzled 5 (FZD5) is highly expressed in ovarian cancer cells, associated with poor prognosis, such as its ligand WNT5a. A humanized monoclonal antibody (mAb) targeting FZD5 is being developed for the treatment of ovarian cancer.
|Target||Frizzled 5 (FZD5)|
|Drug Modality||Monoclonal antibody|
|Mechanism of Action||Wnt signaling pathway stimulants|
We look forward to hearing from you.